Boc-Val-Cit-PAB

• CAT Number: I016635
• CAS Number: 870487-09-5
• Molecular Formula: C₂₃H₃₇N₅O₆
• Molecular Weight: 479.57
• Purity: ≥95%
• Target: ADC Linker
• Storage: 2-8°C
• IUPAC Name: tert-butyl N-[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
• InChI: InChI=1S/C23H37N5O6/c1-14(2)18(28-22(33)34-23(3,4)5)20(31)27-17(7-6-12-25-21(24)32)19(30)26-16-10-8-15(13-29)9-11-16/h8-11,14,17-18,29H,6-7,12-13H2,1-5H3,(H,26,30)(H,27,31)(H,28,33)(H3,24,25,32)/t17-,18-/m0/s1
• InChIKey: VYCVAPFXSOAOCL-ROUUACIJSA-N
• SMILES: CC(C)C(C(=O)NC(CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)CO)NC(=O)OC(C)(C)C

Boc-Val-Cit-PAB（Cat No.:I016635） is a cleavable ADC linker commonly employed in the synthesis of antibody-drug conjugates (ADCs). It stands for tert-butyloxycarbonyl-Valine-Citrulline-p-aminobenzylcarbamate. This linker is designed to connect the cytotoxic drug payload to the antibody via a peptide bond. The Boc protecting group is stable during conjugation and antibody purification, but it can be selectively removed in the tumor microenvironment, triggering drug release. Boc-Val-Cit-PAB provides a versatile and effective strategy for the targeted delivery of potent anticancer drugs through ADC technology.

Reference

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.